Anthony Caggiano, MD, PhD

Oral zervimesine blocks toxic amyloid and alpha-synuclein oligomers, as Cognition maps FDA strategy for Lewy body trials.

CT-1812 shows promise in Lewy body dementia, stabilizing hallucinations and delusions while easing caregiver distress.